GlassScriptPhysician profile
Vivian Wang
NPI 1821416744
$1,264.82
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $532 · 2021: $497.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $299.58 | 2019-2021 | |
| Optinose US, INC. | $209.65 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $199.73 | 2019-2021 | |
| Genzyme Corporation | $144.45 | 2021 | |
| Pfizer INC. | $97.95 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $70.14 | 2019-2020 | |
| Kaleo, INC. | $46.83 | 2019-2020 | |
| Alk-Abello, INC | $41.98 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.79 | 2020 | |
| Octapharma USA, INC. | $31.95 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $29.45 | 2019 | |
| Genentech USA, INC. | $22.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.73 | 2021 | |
| Phadia US INC. | $15.65 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivian Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.